PURPOSE: A phase II study of etoposide (VP 16) and carboplatin (CBDCA) was performed in patients with metastatic neuroblastoma (NB). The aim of the study was to find an alternative treatment for induction with different toxicities than the VP 16/cisplatin (CDDP) combination. PATIENTS AND METHODS: Forty-seven patients who were from 6 months to 16 years of age, with either relapsed (29) or primary resistant (18) NB, were included in a cooperative multicenter phase II study of the French Society of Pediatric Oncology (SFOP). The schedule consisted of 5 consecutive days of VP 16 100 mg/m2/d and CBDCA 160 mg/m2/d. RESULTS: The response rate for the 39 assessable patients was 43%; there were four complete remissions and 13 partial remissions. Neither the status of the patients nor the total dose of CDDP that was received previously influenced response. Hematologic toxicity was marked and caused considerable delay between courses (median interval, 39 days). In these heavily pretreated patients, 16% had a more than 50% decrease in creatinine clearance and a 22% World Health Organization (WHO) grade 2 ototoxicity. CONCLUSION: This VP 16/CBDCA combination deserves further evaluation for efficacy and toxicity in newly diagnosed patients, and the combination of both drugs should be considered for high-dose therapy with bone marrow transplantation.
PURPOSE: A phase II study of etoposide (VP 16) and carboplatin (CBDCA) was performed in patients with metastatic neuroblastoma (NB). The aim of the study was to find an alternative treatment for induction with different toxicities than the VP 16/cisplatin (CDDP) combination. PATIENTS AND METHODS: Forty-seven patients who were from 6 months to 16 years of age, with either relapsed (29) or primary resistant (18) NB, were included in a cooperative multicenter phase II study of the French Society of Pediatric Oncology (SFOP). The schedule consisted of 5 consecutive days of VP 16 100 mg/m2/d and CBDCA 160 mg/m2/d. RESULTS: The response rate for the 39 assessable patients was 43%; there were four complete remissions and 13 partial remissions. Neither the status of the patients nor the total dose of CDDP that was received previously influenced response. Hematologic toxicity was marked and caused considerable delay between courses (median interval, 39 days). In these heavily pretreated patients, 16% had a more than 50% decrease in creatinine clearance and a 22% World Health Organization (WHO) grade 2 ototoxicity. CONCLUSION: This VP 16/CBDCA combination deserves further evaluation for efficacy and toxicity in newly diagnosed patients, and the combination of both drugs should be considered for high-dose therapy with bone marrow transplantation.
Authors: M Grabois; D Frappaz; E Bouffet; C Carrie; D Bouhour; T Philip; M Brunat-Mentigny Journal: Cancer Chemother Pharmacol Date: 1994 Impact factor: 3.333
Authors: Lisa M McGregor; Sheri L Spunt; Victor M Santana; Clinton F Stewart; Deborah A Ward; Amy Watkins; Fred H Laningham; Percy Ivy; Wayne L Furman; Maryam Fouladi Journal: Cancer Date: 2009-02-01 Impact factor: 6.860
Authors: S Proust-Houdemont; C Pasqualini; P Blanchard; C Dufour; E Benhamou; G Goma; M Semeraro; M-A Raquin; O Hartmann; D Valteau-Couanet Journal: Bone Marrow Transplant Date: 2016-04-04 Impact factor: 5.483
Authors: Eva Clemens; Marry M van den Heuvel-Eibrink; Renée L Mulder; Leontien C M Kremer; Melissa M Hudson; Roderick Skinner; Louis S Constine; Johnnie K Bass; Claudia E Kuehni; Thorsten Langer; Elvira C van Dalen; Edith Bardi; Nicolas-Xavier Bonne; Penelope R Brock; Beth Brooks; Bruce Carleton; Eric Caron; Kay W Chang; Karen Johnston; Kristin Knight; Paul C Nathan; Etan Orgel; Pinki K Prasad; Jan Rottenberg; Katrin Scheinemann; Andrica C H de Vries; Thomas Walwyn; Annette Weiss; Antoinette Am Zehnhoff-Dinnesen; Richard J Cohn; Wendy Landier Journal: Lancet Oncol Date: 2019-01 Impact factor: 54.433
Authors: V Minard; O Hartmann; M C Peyroulet; J Michon; C Coze; A S Defachelle; O Lejars; Y Perel; C Bergeron; P Boutard; G Leverger; J L Stephan; A Thyss; P Chastagner; G Couillault; C Devalck; P Lutz; F Mechinaud; F Millot; D Plantaz; X Rialland; H Rubie Journal: Br J Cancer Date: 2000-10 Impact factor: 7.640
Authors: S Mastrangelo; A Tornesello; L Diociaiuti; A Pession; A Prete; V Rufini; L Troncone; R Mastrangelo Journal: Br J Cancer Date: 2001-02 Impact factor: 7.640
Authors: H Rubie; J Michon; D Plantaz; M C Peyroulet; C Coze; D Frappaz; P Chastagner; M C Baranzelli; F Méchinaud; P Boutard; P Lutz; Y Perel; G Leverger; L de Lumley; F Millot; J L Stéphan; G Margueritte; O Hartmann Journal: Br J Cancer Date: 1998-06 Impact factor: 7.640